A V Mukhomedzyanov Selected Research

Infarction (Infarctions)

3/2024	Activation of Cardiac δ2-Opioid Receptors Increases Heart Tolerance to Reperfusion.
1/2024	Comparative Analysis of Infarct-Limiting Activity of Peptide and Non-Peptide δ- and κ-Opioid Receptor Agonists during Heart Reperfusion In Vivo.
5/2023	Role of PI3K, ERK1/2, and JAK2 Kinases in the Cardioprotective Effect of Deltorphin II during Cardiac Reperfusion.
4/2023	The Role of NO Synthase, MPT pore, and Protein Kinase A in the Cardioprotective Effect of the Opioid Receptor Agonist Deltorphin II.
1/2023	Participation of Leptin and Corticosterone in the Decrease in Infarct-Limiting Efficiency of Remote Postconditioning and in the Development of Arterial Hypertension in Metabolic Syndrome in Rats.
5/2022	δ2-Opioid Receptors as a Target in Designing New Cardioprotective Drugs: the Role of Protein Kinase C, AMPK, and Sarcolemmal KATP Channels.
4/2021	Cardioprotective Effect of Opioids, Derivatives of Amide N-Methyl-2-(Pirrolidin-1-yl)Cyclohexyl-1-Amine, under Conditions of Ischemia/Reperfusion of the Heart.
3/2021	Comparative Analysis of Infarct Size Limiting Activity of κ-Opioid Receptor Agonists in In Vivo Reperfused Heart.
3/2021	Comparative Analysis of Infarct Size Limiting Activity of δ-Opioid Receptor Agonists in Reperfused Heart In Vivo.
1/2021	Activation of Peripheral Opioid Kappa1 Receptor Prevents Cardiac Reperfusion Injury.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

A V Mukhomedzyanov Research Topics

Disease

12	Infarction (Infarctions) 03/2024 - 01/2016
9	Ischemia 03/2024 - 04/2015
5	Reperfusion Injury 01/2021 - 01/2016
4	Coronary Occlusion 01/2024 - 05/2016
2	Hypoxia (Hypoxemia) 02/2024 - 12/2019
1	Obesity 01/2023
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2023
1	Hypertension (High Blood Pressure) 01/2023
1	Bradycardia 01/2021
1	Myocardial Infarction 01/2017
1	Heart Injuries 05/2016

Drug/Important Bio-Agent (IBA)

7	Ala(2)- deltorphin IIIBA 03/2024 - 01/2017
6	Opioid Receptors (Opioid Receptor)IBA 01/2024 - 10/2015
4	Naltrexone (ReVia)FDA LinkGeneric 04/2021 - 01/2021
3	Narcotic Antagonists (Opioid Antagonists)IBA 02/2024 - 01/2021
3	norbinaltorphimineIBA 02/2024 - 01/2021
3	N-methylnaloxoneIBA 02/2024 - 01/2021
2	naltrindole benzofuranIBA 02/2024 - 03/2021
2	Opioid Analgesics (Opioids)IBA 04/2021 - 01/2021
2	ICI 199441IBA 01/2021 - 10/2015
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 02/2024
1	Peptides (Polypeptides)IBA 01/2024
1	N,N''- 1,4- butanediylbis(N'- (3- isothiocyanatophenyl))thioureaIBA 05/2023
1	Neuroprotective AgentsIBA 05/2023
1	purinoceptor P2Y6IBA 05/2023
1	Cytidine Diphosphate Choline (Citicoline)IBA 05/2023
1	LeptinIBA 01/2023
1	CorticosteroneIBA 01/2023
1	LipidsIBA 01/2023
1	Adenosine Triphosphate (ATP)IBA 05/2022
1	Protein Kinase CIBA 05/2022
1	(trans)-Isomer 3,4- Dichloro- N- methyl- N- (2- (1- pyrrolidinyl)- cyclohexyl)- benzeneacetamideIBA 04/2021
1	AmidesIBA 04/2021
1	Toxic ActionsIBA 03/2021
1	BW 373U86IBA 03/2021
1	D-Penicillamine (2,5)- EnkephalinIBA 03/2021
1	ChloraloseIBA 03/2021
1	kappa Opioid Receptors (kappa Opioid Receptor)IBA 01/2021
1	tyrosyl- tetrahydroisoquinolinecarbonyl- psi(methylamino)phenylalanyl- phenylalanineIBA 01/2021
1	ORALIT (ORS)IBA 12/2019
1	Oxygen (Dioxygen)IBA 12/2019
1	endomorphin 2IBA 11/2016
1	endomorphin 1IBA 11/2016
1	Verapamil (Calan)FDA LinkGeneric 05/2016
1	Propranolol (Inderal)FDA LinkGeneric 05/2016
1	Adrenergic Receptors (Adrenergic Receptor)IBA 05/2016
1	Nadolol (Corgard)FDA LinkGeneric 05/2016
1	Adenosine (Adenocard)FDA LinkGeneric 01/2016
1	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2016
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2015
1	Tyrosine (L-Tyrosine)FDA Link 04/2015
1	Phosphotransferases (Kinase)IBA 04/2015

Therapy/Procedure

1	Tourniquets 01/2023
1	Ischemic Postconditioning 01/2023
1	Intravenous Infusions 01/2016